Managing the Mental Distress of the Hematopoietic Stem Cell Transplant (HSCT) Patient: a Focus on Delirium

Joseph Bubalo

    Research output: Contribution to journalReview article

    1 Citation (Scopus)

    Abstract

    Purpose of Review: To highlight the breadth and types of mental distress experienced by hematopoietic stem cell transplant (HSCT) patients and highlight the need for better prevention and management of delirium. Recent Findings: Recent publications highlight additional risks factors which predict for mental distress during the HSCT process. Despite new medications and additional psychological reports, there is little progress in non-pharmacologic or medication therapy in the prevention and treatment of delirium. Summary: Mental distress, especially delirium, is common during the HSCT process. The morbidity associated with delirium and other mental distress can still be significant at 6–12 months after the completion of the procedure affecting patient functioning and quality of life (QOL). Medication interventions may be helpful but should be used sparingly for targeted patients during HSCT. Additional interventions are needed to prevent and treat delirium in HSCT patients.

    Original languageEnglish (US)
    Pages (from-to)109-113
    Number of pages5
    JournalCurrent Hematologic Malignancy Reports
    Volume13
    Issue number2
    DOIs
    StatePublished - Apr 1 2018

    Fingerprint

    Delirium
    Hematopoietic Stem Cells
    Transplants
    Quality of Life
    Psychology
    Morbidity
    Therapeutics

    Keywords

    • Delirium
    • Hematopoietic stem cell transplantation
    • Mental distress

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Cite this

    Managing the Mental Distress of the Hematopoietic Stem Cell Transplant (HSCT) Patient : a Focus on Delirium. / Bubalo, Joseph.

    In: Current Hematologic Malignancy Reports, Vol. 13, No. 2, 01.04.2018, p. 109-113.

    Research output: Contribution to journalReview article

    @article{74bc7524f5b1428cbb0ad884860eff7b,
    title = "Managing the Mental Distress of the Hematopoietic Stem Cell Transplant (HSCT) Patient: a Focus on Delirium",
    abstract = "Purpose of Review: To highlight the breadth and types of mental distress experienced by hematopoietic stem cell transplant (HSCT) patients and highlight the need for better prevention and management of delirium. Recent Findings: Recent publications highlight additional risks factors which predict for mental distress during the HSCT process. Despite new medications and additional psychological reports, there is little progress in non-pharmacologic or medication therapy in the prevention and treatment of delirium. Summary: Mental distress, especially delirium, is common during the HSCT process. The morbidity associated with delirium and other mental distress can still be significant at 6–12 months after the completion of the procedure affecting patient functioning and quality of life (QOL). Medication interventions may be helpful but should be used sparingly for targeted patients during HSCT. Additional interventions are needed to prevent and treat delirium in HSCT patients.",
    keywords = "Delirium, Hematopoietic stem cell transplantation, Mental distress",
    author = "Joseph Bubalo",
    year = "2018",
    month = "4",
    day = "1",
    doi = "10.1007/s11899-018-0441-2",
    language = "English (US)",
    volume = "13",
    pages = "109--113",
    journal = "Current Hematologic Malignancy Reports",
    issn = "1558-8211",
    publisher = "Springer Science + Business Media",
    number = "2",

    }

    TY - JOUR

    T1 - Managing the Mental Distress of the Hematopoietic Stem Cell Transplant (HSCT) Patient

    T2 - a Focus on Delirium

    AU - Bubalo, Joseph

    PY - 2018/4/1

    Y1 - 2018/4/1

    N2 - Purpose of Review: To highlight the breadth and types of mental distress experienced by hematopoietic stem cell transplant (HSCT) patients and highlight the need for better prevention and management of delirium. Recent Findings: Recent publications highlight additional risks factors which predict for mental distress during the HSCT process. Despite new medications and additional psychological reports, there is little progress in non-pharmacologic or medication therapy in the prevention and treatment of delirium. Summary: Mental distress, especially delirium, is common during the HSCT process. The morbidity associated with delirium and other mental distress can still be significant at 6–12 months after the completion of the procedure affecting patient functioning and quality of life (QOL). Medication interventions may be helpful but should be used sparingly for targeted patients during HSCT. Additional interventions are needed to prevent and treat delirium in HSCT patients.

    AB - Purpose of Review: To highlight the breadth and types of mental distress experienced by hematopoietic stem cell transplant (HSCT) patients and highlight the need for better prevention and management of delirium. Recent Findings: Recent publications highlight additional risks factors which predict for mental distress during the HSCT process. Despite new medications and additional psychological reports, there is little progress in non-pharmacologic or medication therapy in the prevention and treatment of delirium. Summary: Mental distress, especially delirium, is common during the HSCT process. The morbidity associated with delirium and other mental distress can still be significant at 6–12 months after the completion of the procedure affecting patient functioning and quality of life (QOL). Medication interventions may be helpful but should be used sparingly for targeted patients during HSCT. Additional interventions are needed to prevent and treat delirium in HSCT patients.

    KW - Delirium

    KW - Hematopoietic stem cell transplantation

    KW - Mental distress

    UR - http://www.scopus.com/inward/record.url?scp=85044992431&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85044992431&partnerID=8YFLogxK

    U2 - 10.1007/s11899-018-0441-2

    DO - 10.1007/s11899-018-0441-2

    M3 - Review article

    C2 - 29404834

    AN - SCOPUS:85044992431

    VL - 13

    SP - 109

    EP - 113

    JO - Current Hematologic Malignancy Reports

    JF - Current Hematologic Malignancy Reports

    SN - 1558-8211

    IS - 2

    ER -